Trial Participation- There is still time to join!

HCM Clinical Trial Opportunities 

We’ve been urging you to learn a few important points about your disease because HCM has various presentations and important metrics.

  • Are you obstructed or non-obstructed?
  • What is your Ejection Fraction – (EF)?
  • What is your NYHA functional class?
  • If you have a genetic mutation, if so, what is it?

Knowing the answers to these questions gives a healthcare provider a snapshot of your disease and also facilitates eligibility for clinical trials.  

Current trials:

  • The first is the Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy (ODYSSEY-HCM). For more information, please complete this survey:
  • Other myosin inhibitor trials regarding the Efficacy and Safety of Aficamten. For information about this and other trials, please complete the survey:
  • MyPeak-1 is actively enrolling patients with nonobstructive HCM who have the MYBPC3 genetic mutation. For more information, please complete this survey:
  • For our younger HCM community members with the MYBPC3 gene, a study: Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy (MyCLIMB).

If you are interested in any of these trial opportunities, please send me an email with your contact information – my email is

If you haven’t gone through the HCMA Intake process within the last two years, please schedule an Intake Call on the website

This will give us the best understanding of your current health, HCM presentation, and potential eligibility in upcoming trials.

Leave a Comment